SSIIHealthcare · Medical DevicesThe 1 Wall Street analysts covering SS Innovations International, Inc. hold a median 12-month price target of $7 — +197.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 24 of 100 as at 31 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores SS Innovations International, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (68): Analysts have, on balance, been raising their forecasts.
Volatility (13): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on SSII, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
The green dot is the last close — the median target sits +197.9% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 3 June 2026 | LUCID CAPITAL MARKETS | Initiates | Buy | $7.00 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
SSII appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 98% of US stocks
Cheaper than 14% of US stocks
Cheaper than 10% of US stocks
Cheaper than 95% of US stocks
Higher than 83% of US stocks
Higher than 71% of US stocks
Higher than 63% of US stocks
Higher than 22% of US stocks
Higher than 15% of US stocks
Higher than 29% of US stocks
Higher than 30% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
SS Innovations International, Inc. has a market value of $471.1M and an enterprise value of $475.1M.
Revenue in the twelve months to 30 June 2026: $52.4M. The latest quarter grew 39.4% year on year.
Net income over the same four quarters: −$12.4M, a −23.7% net margin.
Diluted earnings per share, trailing twelve months: $−0.06.
Free cash flow in the twelve months to 30 June 2026: −$18.2M.
Trailing P/E: −39.2×; forward P/E: −39.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
SS Innovations International, Inc. employs 483 people — $108K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own SS Innovations International, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
SS Innovations said its SSi Mantra surgical robotic system and SSi MantrAsana tele-surgeon console were showcased in telesurgeries during October 2026 conferences hosted by EACTS in Barcelona and SRS India in New Delhi.
Why it matters — The demonstrations highlight the company’s telesurgery capabilities at two medical conferences.
The item says SSII’s revenue growth and adoption of robotic surgery signal growth, while widening losses and financing pressures challenge profitability. Its headline notes a 32% share decline over three months and poses whether to buy the dip or wait.
Why it matters — SSII watchers may weigh signs of business growth against the company’s losses and financing pressures.
SS Innovations said it submitted a response on October 5, 2026, to an FDA request for additional information regarding its 510(k) submission for the SSi Mantra surgical robotic system.
Why it matters — The response is part of the FDA review process for the SSi Mantra system.
The Zacks Investment Research headline places SSII among two international microcaps for a watchlist. The excerpt notes that SSII’s sales are predominantly in India.
Why it matters — The excerpt identifies India as SSII’s primary sales market, offering context on the company’s geographic exposure.
Zacks initiated coverage of SSII with a Neutral rating, describing itself as the first on Wall Street to cover the stock. Its overview cites expanding robotic surgery adoption, rising revenues and international growth, alongside persistent losses and regulatory hurdles.
Why it matters — The initiation gives SSII watchers a new Wall Street assessment that weighs growth factors against ongoing losses and regulatory challenges.
The 1 Wall Street analysts covering SS Innovations International, Inc. have a median 12-month price target of $7, with estimates ranging from $7 to $7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering SS Innovations International, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks SS Innovations International, Inc. 24 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, SS Innovations International, Inc. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (68 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +197.9% from the last close, and Ticker Nerd's factor model ranks SS Innovations International, Inc. 24 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering SS Innovations International, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SSII are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $7 over the next 12 months.
SS Innovations International, Inc. is a medical technology company focused on surgical robotics and related instruments.
The most recent item we track (GlobeNewsWire, 26 Oct 2026): "SS Innovations Showcases SSi Mantra Telesurgery Capabilities at October 2026 Conferences". SS Innovations said its SSi Mantra surgical robotic system and SSi MantrAsana tele-surgeon console were showcased in telesurgeries during October 2026 conferences hosted by EACTS in Barcelona and SRS India in New Delhi.
SS Innovations International, Inc. is a medical technology company focused on surgical robotics and related instruments. The company develops, manufactures, and commercializes robotic-assisted surgery systems designed to support minimally invasive procedures across multiple specialties, including cardiac, urology, gynecology, general surgery, and thoracic care. Its product portfolio centers on the SSi Mantra surgical robotic system and the SSi Mudra line of surgical instruments, which together form an integrated platform for surgeons and hospitals. SS Innovations International serves healthcare providers in India and international markets, where its solutions are used to expand access to advanced robotic surgery and support a broad range of clinical applications. The company operates as a commercial-stage business within the medical devices and healthcare technology sectors.
CEO Dr. Sudhir Prem Srivastava M.D. · 483 employees · India · https://ssinnovations.com